Biofortuna closely monitors the COVID-19 situation on a global basis to maintain the stability of both our and our customers’ supply chains.
We remain 100% guided by the advice of the UK Government and public health bodies on the appropriate ways of working.
A risk assessment and COVID-19 policy is in place to minimise any risk to our staff.
As an ISO 13485 accredited and FDA registered facility we have been inundated with requests for services, reagents and manufacturing support to address the novel SARS-CoV-2 virus.
Over the last two months the Company has responded positively and rapidly to the surge in demand, increasing the number of staff in our manufacturing facility by 400% and increasing output capability to more than 4 million tests per week.
Highlights to date include
Biofortuna’s Genomic Services division supporting COVID-19 Testing
As part of the UK government’s call for private UK based labs to support the national testing effort, Biofortuna is currently supporting the Volunteer Testing Network and running critical screening tests at its dual-site facility